

IDERA PHARMACEUTICALS, INC.
 Form 4
 May 17, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Abdul-Wahab Umari

2. Issuer Name and Ticker or Trading Symbol
 IDERA PHARMACEUTICALS, INC. [IDRA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 05/07/2013

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

CAMBRIDGE, MA 02139

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2013		P	2,600,000 A	\$ 0 0 ⁽⁴⁾	I	See Footnotes <u>(4)</u> <u>(5)</u>
Common Stock	05/07/2013		P	2,400,000 A	\$ 0 0 ⁽⁴⁾	I	See Footnotes <u>(4)</u> <u>(6)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

SEC 1474 (9-02)

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount
Warrants	\$ 0.61	05/07/2013		A	1,000,000		05/07/2013	05/07/2018	Common Stock	1,000,000
Warrants	\$ 0.79	05/07/2013		A	575,758		05/07/2013	06/01/2014	Common Stock	575,758
Warrants	\$ 0.79	05/07/2013		A	313,341		05/07/2013	06/01/2014	Common Stock	313,341
Warrants	\$ 0.79	05/07/2013		A	110,901		05/07/2013	06/01/2014	Common Stock	110,901
Warrants	\$ 0.47	05/07/2013		P	2,600,000		05/07/2013	05/07/2018	Common Stock	2,600,000
Warrants	\$ 0.47	05/07/2013		P	2,400,000		05/07/2013	05/07/2018	Common Stock	2,400,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Abdul-Wahab Umari C/O IDERA PHARMACEUTICALS, INC. 167 SIDNEY STREET CAMBRIDGE, MA 02139	X			

Signatures

/s/ Abdul-Wahab Umari
Umari
05/17/2013
Date

Signature of Reporting
Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) On May 7, 2013, upon the consummation of a public offering of the Issuer (the "Offering"), Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner, acquired, directly from the Issuer, warrants to purchase up to 1,575,758 shares of common stock (the "Pillar I Shares") of the Issuer.

On May 7, 2013, upon the consummation of the Offering, Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner, acquired, directly from the Issuer, warrants to purchase up to 313,341 shares of common stock (the "Pillar II Shares") of the Issuer.
 - (3) On May 7, 2013, upon the consummation of the Offering, Participations Besancon ("Besancon"), a fund advised by Pillar GP, acquired, directly from the Issuer, warrants to purchase up to 110,901 shares of common stock (the "Besancon Warrants").

Abdul-Wahab Umari is a director of Pillar GP and serves as the representative of a Pillar I, Pillar II, Pillar III and Pillar GP on the Issuer's board of directors. Mr. Umari disclaims Section 16 beneficial ownership of the Pillar I Shares, Pillar II Shares, Pillar III Shares, Besancon Warrants and Besancon Shares and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. Umari owns directly 46,117 shares of common stock of the Issuer.
 - (5) On May 7, 2013, upon the consummation of the Offering, Pillar Pharmaceuticals III, L.P. ("Pillar III"), of which Pillar GP is the general partner, acquired, in the Offering, 2,600,000 shares of common stock and warrants to purchase up to 2,600,000 shares of common stock (the "Pillar III Shares") of the Issuer.
 - (6) On May 7, 2013, upon the consummation of the Offering, Participations Besancon acquired, in the Offering, 2,400,000 shares of common stock and warrants to purchase up to 2,400,000 shares of common stock (the "Besancon Shares").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.